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ABSTRACT 
Background: The aim of our study was to measure drug-related changes in hemodynamics and oxygen 
metabolism in response to different doses of an age-appropriate dobutamine formulation in hypoxic pigs. 
A secondary aim was to validate superior vena cava flow (SVCF) as a marker of cardiac index (CI) for 
subsequent clinical trials of this formulation in humans. 
Methods: Newborn pigs (n=18) were exposed to 2h-hypoxia (10-15% oxygen) followed by reoxygenation 
(21-30% oxygen 4h). After 1h-reoxygenation, pigs were randomized to: control group (no treatment), 
dobutamine infusion at a rate of 10-15µg/kg/min or 15-20µg/kg/min. Dobutamine groups received two 
dobutamine doses during 30min with a 60min washout period between doses. Cardiovascular profile and 
oxygen metabolism were monitored. In four animals an ultrasonic perivascular flow probe was placed 
around superior vena cava to measure SVCF.  
Results: Hypoxia significantly decreased CI, systemic-vascular-resistance and mean-arterial-blood-
pressure (MABP). Dobutamine doses significantly increased heart-rate, CI and oxygen-delivery without 
changes in stroke-volume and MABP. Only 10-15µg/kg/min increased oxygen consumption and 
peripheral tissue oxygenation measured by Near-infrared-spectroscopy. A positive correlation was 
observed between SVCF and CI. 
Conclusion: The new pediatric dobutamine formulation improved hemodynamic status, with dose-specific 
differences in metabolic response. SVCF may be a useful surrogate for CI in subsequent clinical trials. 
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INTRODUCTION 
Neonatal asphyxia frequently leads to shock, myocardial dysfunction, pulmonary hypertension, poor 
regional perfusion, inadequate tissue oxygen delivery, impaired cerebral blood flow (CBF) autoregulation, 
and, potentially, end-organ injury and death (1). Importantly, in neonates surviving asphyxia there is a risk 
of subsequent neurological injury. 
Inotropes are often used in asphyxiated infants who are exhibiting signs of cardiovascular 
compromise. Dobutamine, dopamine, and epinephrine are commonly used inotropes. However these 
drugs are currently used off label with there being little in the way of safety or efficacy data for their use in 
neonates. Specifically, dobutamine, a semisynthetic sympathomimetic drug,  has been used off-label in 
newborns and children for over 20 years to enhance cardiac output (2). The importance of using licensed 
age-appropriate drug formulations is now recognized by regulatory agencies, clinicians and investigators 
(3).   
In the light of the EU and USA new drug regulations on medicines for children a need exists for an 
age-appropriate formulation for dobutamine. Much of our current understanding of the pathophysiology of 
perinatal disorders has evolved from animal studies. The piglet model can be used to study perinatal 
hypoxia: the newborn piglet has a development similar to the 36-38 weeks human fetus (4). Moreover 
they share with human similar anatomic and physiologic characteristics involving the cardiovascular (with 
a histological appearance of the myocardium nearly identical) and other systems. These characteristics 
confer major advantages over models in other species; moreover its size allows the instrumentation and 
monitoring systemic and regional hemodynamic changes, tissue perfusion and oxygen demand. Our 
animal experiments were part of a larger NEO-CIRC European project (FP7_HEALTH grant agreement 
282533) which studies a new age appropriate (for use in newborns in the first 72 hours of life) 
dobutamine formulation in order to increase availability of medicines authorized for children as well as to 
increase the information available on the use of medicinal products in the pediatric population. 
A key factor to obtain safety and efficacy data from clinical trials of inotropes such as dobutamine is an 
objective measure of cardiac output (CO), and hence cardiac Index (CI, calculated as CO divided by 
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animal weight). CO is linked to systemic blood flow (and hence tissue perfusion), but the presence of 
ductal and atrial shunts in some neonates limits the usefulness of this approach and so newer ways of 
measuring systemic blood flow are needed. (5). Echocardiographic measurements of superior vena cava 
blood flow (SVCF) may provide a more reliable indication of neonatal systemic perfusion and could be 
used primarily in premature neonates to assess CO independent of the transitional circulation shunts. 
SVCF is potentially a proxy measure for CBF (6), and low SVCF has been associated with neurological 
injury in premature neonates.  
The primary aim of the study was to measure the effects of different doses of a new pediatric 
formulation of dobutamine on hemodynamic and oxygen metabolism in hypoxic neonatal piglets. Our 
secondary aim was to validate SVCF as a marker of CI in neonatal asphyxiated piglets with normal and 
low CO. Furthermore we evaluated changes in biochemical parameters and cardiac histological samples 
after dobutamine administration. 
RESULTS 
The subsequent results are displayed as mean and standard deviation. The piglets were 2.0±0.9 day-
old, weighing 1.7±0.2 kg with no statistically-significant differences noted in  any of the baseline values 
between each group. Three piglets died during hypoxia and their data were excluded from the study. 
Two hours of hypoxia resulted in severe metabolic acidosis (pH: 6.81-6.96; base excess (BE): -24.9- 
22.2 mmol/l) with a significant increase in lactate concentration (16.5-18.1 mmol/l) and normocapnia (41-
44 mmHg) (Table 1). With the first dose of dobutamine (10 µg/kg/min in low to medium (L-M) group and 
15 µg/kg/min in medium to high (M-H) group) pH, BE and lactate concentration demonstrated a significant 
improvement compared to control group (Table 1). These findings were also replicated after second 
dobutamine dose in both dobutamine groups (Table 1). 
Superior vena cava flow (SVCF) vs. Cardiac Index (CI) correlation 
32 correlations were calculated between SVCF with CI in four animals. A good positive correlation (r2 
= 0.645) was observed when SVCF was compared with CI (p<0.0001) (Figure 1). At baseline, the 
animals showed a SVCF of 75±17 ml/min/kg that decreased to 45±1 ml/kg/min during hypoxia. 
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Systemic hemodynamic responses 
There were no baseline differences among groups in the cardiovascular parameters studied (Figure 2 
and 3). Two hours of hypoxia resulted in a significant decrease in both CI (mean CI: 228-242 vs. 327-425 
ml/kg/min) and systemic vascular resistance index (SVRI) (mean SVRI: 0.10-0.14 vs. 0.19-0.24 
mmHg/kg/min) and severe reduction in mean arterial blood pressure (MABP) (mean MABP: 32-34 vs. 75-
89 mmHg) in comparison with baseline values (p<0.05 in all cases), but no significant changes in stroke 
volume index (SVI) or heart rate (HR).  
All dobutamine doses significantly increased CI with an increase in HR and a significant decrease of 
SVRI compared to pretreatment points but with no change in SVI (Figure 2 and 3). However, only the M-
H group showed higher CI and lower SVRI than controls with a significant increase in HR, at two given 
dobutamine doses (15 and 20 µg/kg/min) while L-M group showed a significant increase of CI with an 
increase in HR only after 15 µg/kg/min dobutamine administration compared to controls.  
Mean arterial blood pressure values fell below baseline values after hypoxia, during reoxygenation and 
after different dobutamine dose administration. MABP was maintained stable along the time without 
significant alteration between groups. Meanwhile, central venous pressure (CVP) of 6-8 mmHg was 
maintained without changes among groups or in relation to any of the doses.  
Systemic oxygen metabolism and transport 
At baseline there were no differences among groups in any of the systemic oxygen metabolism and 
transport parameters. Two hours of hypoxia produced a significant decrease in arterial oxygen content 
(CaO2), oxygen delivery (OD) and oxygen consumption (VO2) (Table 1 and Figure 4) with a significant 
increment of systemic fractional oxygen extraction (FTOE) (p<0.05 vs. baseline). 
The administration of all dobutamine doses produced a significant increase in OD in comparison to 
controls. However, only the 10-15 µg/kg/min dobutamine doses resulted in VO2 increment without 
changes in CaO2 and FTOE.  
Peripheral tissue oxygenation index (pTOI) and peripheral intravascular oxygenation (pIO2) measured 
by near-infrared spectroscopy (NIRS) showed a significant decrease at the end of hypoxia (pTOI: 58±5 
vs. 26±9; pIO2: -2±2 vs. -53±6). After 60 min of reoxygenation these parameters recovered partially in all 
Ac
ce
pt
ed
ma
nu
sc
rip
t
ACCEPTED ARTICLE PREVIEW 
© 2016 International Pediatric Research Foundation, Inc. All rights reserved 
animals (pTOI: 49±5; pIO2: -19±5). Only the L-M group showed a significant improvement of regional 
circulation and oxygen saturation after first (pTOI: 54±4 vs. 49±5; pIO2: -10±4 vs. -19±5) and second 
(pTOI: 56±3 vs. 52±4; pIO2: -6±3 vs. -13±2) dobutamine dose administration compared to baseline. 
Biochemical and histological analysis 
Baseline serum cardiac troponin T levels were 202±124 pg/ml. After 6 hours of experimental period 
the controls showed a non-significant increase of troponin T levels to 317±159 pg/ml. In contrast, the 
piglets given dobutamine groups showed similar cardiac troponin T levels compared to baseline (L-M 
group: 171±38 pg/ml and M-H group: 186±97 pg/ml). At the end of the experimental period serum 
creatine kinase  (CK) activity was significantly increased in controls (121±63 U/l) in comparison with 15-20 
µg/kg/min (43±6 U/l) (p<0.05) and 10-15 µg/kg/min (58±18 U/l) (p=0.06). 
Necropsies at the end of the experiment revealed acute hemorrhagic foci and mild diffuse congestion 
in myocardium in 4 of the 6 controls. However, ventricular pathological changes were observed in only 
one animal in the 10-15 µg/kg/min dobutamine group and in two animals in 15-20 µg/kg/min dobutamine 
group. 
DISCUSSION 
In these newborn piglets, induction of hypoxia led to cardiovascular abnormalities such as 
hypotension, metabolic acidosis, decrease in CI and SVCF as well as an increase in biochemical markers 
such as serum troponin T and CK. We found that the new dobutamine formulation causes a significant 
increase in CI, HR and OD without changes in MABP or SV. Only the administration of 10-15 µg/kg/min 
showed a significant increase in VO2 and pTOI and pIO2. 
SVCF can be used to assess systemic blood flow in newborn infants, of which approximately 80% 
goes to the brain (7). In the crucial early postnatal period SVCF may allow for a more accurate 
assessment of the status of systemic blood flow and response to different treatments as it is unaffected 
by cardiac shunting from the patent foramen ovale or ductus arteriosus (8). Although echocardiographic 
SVCF measurements are used in neonates, in newborn piglets it is quite difficult due to the piglet chest 
anatomy. To overcome this problem, we measured SVCF using a transit time ultrasound flow probe which 
is considered the standard reference method for cardiac output measurements in an animal model (9). In 
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our model, a positive correlation was observed when SVCF was compared with CI before, after hypoxia 
period and during dobutamine administration. Whilst it must be acknowledged that the method used to 
measure SVCF is very different to that used in human neonates, this study indicates that it is a biomarker, 
when measured accurately, reflects systemic blood flow. This is backed up by recent research showing 
that a new modified echocardiographic technique of measuring SVCF in human neonates correlates 
better with phased contract MRI measurements of SVCF.  
In neonatal asphyxia, it is important to monitor CO and blood pressure because multisystem 
involvement includes hypotension and low CO. CO measurement using a technique of transpulmonary 
indicator dilution or ventricular outputs by echocardiography has been increasingly used (10). 
Dobutamine is a drug that primarily stimulates beta-1 receptors, leading to increase inotropic and 
chronotropic effects and to a lesser extent, stimulates beta-2 adrenergic receptors, leading to 
vasodilatation (decrease of SVRI). This combination of effects contributes to increase CO with decreased 
SVR (11,12). Previous animal research using neonatal animal models have observed that during the 
short-term dobutamine administration (10 min) the increase in CO is related to the chronotropic effects 
(increasing HR) (13), whereas the long-term (2 h) infusion demonstrated inotropic effects (increasing SV) 
(14).  In our study, we found that the increase in CO after short-time dobutamine infusion was mainly due 
to the increased in HR rather than SV. Interestingly due to hypoxia, the piglets had high HR values prior 
to dobutamine administration, so although the increase in CO was found to be directly related to HR, this 
effect was attenuated at HR values of approximately 250 bpm, attenuating the dose-response effect. 
Neonates reliance on increasing CO through increasing their HR relates to a reduced ventricular diastolic 
compliance and an under-development of the neonatal myocyte making the heart less able to respond to 
volume loading (15).  
The effect of dobutamine on MABP during neonatal period was variable. Consistent with other reports, 
our findings showed that dobutamine infusion had no significant effect on MABP (14, 16). A weak 
correlation between MABP and CO in preterm infants has been demonstrated (17) this is why MABP is 
not considered a good marker for CO. Therefore, the use of MABP as a measure of the inotropic action of 
dobutamine is unreliable, and direct flow measurement is needed. In fact, at short term infusions, 
dobutamine did not correct the low MABP seen in hypoxic piglets, although it did increase CO and SVCF. 
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These data are similar to that obtained by Devictor et al in 1988 in 6 full term human neonates with 
severe perinatal asphyxia. They demonstrated a significantly increased in CO, HR and aortic blood flow 
velocity after 10 micrograms/kg/min of dobutamine administration (18). The MABP increased but not 
significantly and SV remained unchanged (18). Therefore for effective increases in MABP and CO while 
caring for newborn infants recovering from perinatal asphyxia, another agent with vasopressive action 
such as dopamine or noradrenaline may be added to dobutamine infusion. 
In our study severe hypoxia resulted in a significant decrease of CaO2, and VO2 with an increase of 
FTOE due to the decrease in OD. Moreover, the reoxygenation period resulted in a recovery of VO2 
values with a partial recovery of FTOE and OD. Dobutamine therapy has been suggested to increase 
tissue metabolic rate in healthy newborn lambs (19) whereas in hypoxic piglets OD increase was not 
accompanied by changes in VO2 or FTOE (16). In our study, the administration of 10-15 µg/kg/min of 
dobutamine in hypoxic newborn piglets produced a significant increase in VO2 probably due to the effect 
of dobutamine on OD (due to better CI) without changes in CaO2 and FTOE, while higher dobutamine 
doses did not show significant increase of VO2. This effect has also been previously observed in adult 
patients where dobutamine effects on oxygen metabolism were observed at lower doses but not at higher 
doses (20). To assess if these changes would have beneficial effects the infusion and experiment 
duration should be maintained over a prolonged period of time. 
There is a great interest in the use of NIRS technology in the neonatal intensive care unit (NICU) as a 
continuous, non-invasive bedside monitoring technique to monitor adequacy of tissue oxygen metabolism 
and perfusion (21). Measurements of the renal pTOI and pIO2 give insight into peripheral perfusion in 
general and into renal end-organ function (22, 23). Regional saturation changes exceeding >20% from 
baseline would be reason for concern and may indicate compromised perfusion. In our experiment, renal 
pTOI and pIO2 measured by NIRS showed a significant decrease (> 40%) during hypoxia, suggesting a 
compromise in peripheral perfusion. During reoxygenation these values were partially restored and only 
in L-M group the administration of dobutamine doses result in an improvement of regional circulation and 
oxygen saturation. This effect in regional tissue oxygenation during low to medium dobutamine infusion 
was also observed in healthy neonatal piglets (24), not found differences at higher doses.  
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Limitations 
This experimental piglet model used in our study attempts to mimic the clinical phenomenon of 
neonatal hypoxia that results in low CO, hypotension and a profound metabolic acidosis. However, as 
with all animal models of human disease there may be inter-species differences that limit the 
transferability of any results. For example, our piglet model of hypoxia does not seem to induce the 
hypercapnia seen with human neonates experiencing asphyxia which may influence the cardiovascular 
recovery. It is important to also recognize that the invasive method of measuring SVCF is very different to 
what is used in the clinical domain. However this is due to the constraints of the thoracic cavity.  
CONCLUSION 
In summary, the new pediatric dobutamine formulation improved hemodynamic status in hypoxic 
neonatal piglets, with dose-specific differences in metabolic response. SVCF seems to be a promising 
measure of CO and we will be investigating its value in subsequent longer-term clinical trials of this new 
formulation. The pattern of change seen in response to the new dobutamine was encouraging and 
justifies longer-term studies in human neonates. 
The new age appropriated dobutamine formulation due to the reduction of sodium metabisulfite levels 
and presentation, is expected to improve safety in relation to possible adverse events and potential 
medication errors. So, further studies are needed to evaluate long-term multisystem organ functions and 
neurodevelopmental outcome. 
METHODS 
We obtained 18 newborn piglets (age 2-4 days, 1.7±0.2 kg) of both sexes from a local farm on the 
morning of the experiment. This study was carried out in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals. The experimental protocol met European and 
Spanish regulations for protection of experimental animals (2010/63/UE and RD53/2013) and was 
approved by the Ethical Committee for Animal Welfare of the Cruces University Hospital, Spain (EU-
03.BI#013_11). 
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Surgical preparation 
The animals were sedated with intramuscular ketamine (15 mg/kg) and diazepam (2 mg/kg). 
Analgesia and anaesthesia were induced by intravenous (IV) fentanyl (5 micrograms/kg) and propofol 
(1.2 mg/kg) respectively and maintained by a continuous infusion of fentanyl (5-20 µg/kg/h) and propofol 
(2-3 mg/kg/h) administered through an ear vein. At the same time, the animals were paralysed using a 
continuous IV infusion of vecuronium bromide (3 mg/kg/h). A continuous three-lead ECG was established 
in all animals. 
 After a tracheotomy we inserted a 4.0 mm ID tracheal tube, connected to a neonatal ventilator (VIP 
Bird, Bird Products Corp., Palm Springs, CA) with the following initial settings: fraction of inspired oxygen 
(FiO2) =0.25, respiratory frequency (fR) =20 breaths/min, positive end-expiratory pressure (PEEP) =3 
cmH2O and positive inspiratory pressure (PIP) =10 cmH2O. Deviations from acceptable blood gases 
values (PaO2 90–110 mmHg, PaCO2 35–45 mmHg and pH 7.35–7.45) were corrected by adjusting the 
ventilator settings and/or by adding sodium bicarbonate as needed. 
A thermodilution arterial catheter (5Fr, PiCCO Plus, Pulsion, München, Germany) was inserted into 
the femoral artery to monitor MABP and HR, to measure CO and to obtain arterial blood samples for 
blood gas analysis (PaO2, PaCO2, pH, Base Excess (BE), SaO2), lactate and haemoglobin (Hb) (GEM 
Premier 4000, Instrumentation Laboratory Company, Lexington, MA). In addition, a 5 Fr three-lumen 
catheter was inserted into the internal jugular vein to inject cold saline, to monitor CVP, to maintain fluids 
(10% dextrose-saline at 5 ml/kg/h) and to obtain blood samples for blood gas analysis and for 
biochemical analysis. Finally, a 5 Fr three-lumen catheter was inserted into the femoral vein for IV 
infusion of dobutamine with an infusion pump (Alaris System with Guardarails, Cardinal Health, San 
Diego, CA). Blood temperature, measured by a thermistor at the thermodilution arterial catheter tip, was 
maintained at 38-39ºC using an overhead warmer along the experiment. 
Correlation studies of SVCF vs. CI 
To measure SVCF, a left anterior thoracotomy was performed in the first intercostal space in four 
animals. The superior venous cava was isolated and a non-invasive perivascular Doppler flow probe 
(MA3PS, Transonics, Ithaca, FL) was placed around it to continuously measure SVCF. SVCF values 
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were compared to the CI measured by thermodilution at different time points during experimental 
procedure (baseline, hypoxia, reoxygenation and dobutamine administration). Briefly, 3ml of cold saline 
(<8ºC) was injected into the central venous catheter. The injectate rapidly disperses volumetrically and 
thermally within the pulmonary and cardiac volumes. This volume of distribution is termed the 
intrathoracic volume. When the thermal signal reaches the thermistor-tipped in the femoral catheter, a 
temperature difference is detected and a dissipation curve is generated. Then the monitor use specific 
algorithms to determine the cardiac output by integrating the area under the curve of the arterial pressure 
vs. time trace. 
Experimental design 
Following surgery, the piglets were allowed to stabilise until baseline hemodynamic measures were 
stable (changes less than 10% over a 30-minute period). Preliminary arterial blood gas analysis was 
performed at this time to ensure that pH, PaO2 and  PaCO2 values were within acceptable limits. After 
stabilization, hypoxia was induced (FiO2: 0.1-0.15) by increasing the concentration of inhaled nitrogen gas 
for 120 min (25). At that moment animals were randomly assigned to: 
 1) Control group (n=6): following 60 min of reoxygenation (FiO2: 0.21- 0.30) animals were maintained 
without dobutamine treatment after the end of the experimental period;  
2) Low to Medium dose group (L-M group) (n=6): after 60 min of reoxygenation (FiO2: 0.21- 0.30), 
each animal received two doses of the new pediatric dobutamine formulation (Proveca LTD, Daresbury, 
Cheshire, UK) during 30 min (10 µg/kg/min and 15 µg/kg/min) with 60 min washout period between doses 
and after discontinuation of medication. All infusions was administered with an infusion pump, and  
3) Medium to High dose group (M-H group) (n=6): after 60 min of reoxygenation (FiO2: 0.21- 0.30), 
each animal received two doses of the new pediatric dobutamine formulation during 30 min (15 µg/kg/min 
and 20 µg/kg/min) with 60 min washout period between doses and after discontinuation of medication. 
The experimental design is shown in figure 5. 
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Dobutamine formulation 
The new pediatric formulation of dobutamine HCl solution (12.5 mg/ml in 5 ml glass vials, Proveca 
LTD, Daresbury, Cheshire, UK) for injection is novel and investigational, containing half the quantity of 
antioxidant (sodium metabisulfite) compared to other marketed formulations due to concerns over the 
toxicity of this preservative in neonates. The manufacturing process is also novel, and uses nitrogen 
infusion and blanketing to limit the oxygen content the headspace of the vial, thereby limiting the rate of 
degradation of the dobutamine. 
Measurements 
At different time points (figure 5), blood samples were drawn from the femoral artery and the jugular 
vein to obtain blood samples to measure blood gases, base excess, lactate, and to perform biochemical 
analysis. 
Animals were monitored for MABP, HR, CO, SVI, CVP and temperature (IntelliVue MP50, Phillips, The 
Netherlands) specifically before and after any intervention (figure 5). The following variables were 
calculated:  
1- Cardiac index (CI) (ml/kg/min) = CO ÷ weight 
2- Systemic vascular resistance index (SVRI) (mmHg/ml.kg-1.min-1) = (MABP-CVP) ÷ CI 
3- Systemic arterial (venous) oxygen content (Ca(v)O2) (O2 ml/dl) = (Sa(v)O2 x Hb x 1.39/100) + 
(Pa(v)O2 x 0.003) 
4- Systemic oxygen delivery (OD) (O2 ml/kg/min) = CaO2 x CI 
5- Systemic oxygen consumption (VO2) (O2 ml/kg/min) = (CaO2 – CvO2) x CI 
6- Systemic fractional oxygen extraction (FTOE) = (SaO2 – SvO2) ÷ SaO2 
Change in peripheral perfusion-oxygenation was assessed using a commercial continuous-wave 
method with a near-infrared spatially-resolved spectroscopy (NIRS) instrument (NIRO 200 Hamamatsu 
Photonics, Hamamatsu, Japan). Laser diodes produce light in the near-infrared range that is transmitted 
thorough a fibreoptic bundle. The relative absorption coefficients obtained are used to calculate the tissue 
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oxygenation index (TOI) in percent, that is, the ratio of oxyhaemoglobin (O2Hb) to total haemoglobin 
(tHb), total haemoglobin being calculated as the sum of O2Hb and deoxyhaemoglobin (HHb). pIO2 and 
pTOI were continuously monitored. Changes in pIO2, equivalent to the difference between O2Hb and 
HHb, were used as a surrogate of changes in peripheral blood flow whereas pTOI was used to estimate 
venous oxygen saturation (pSvO2) (26). Due to the small size and the thin covering layers of tissue of 
term, the sensor was placed in the renal region (renal fossa) in order to evaluate changes in peripheral 
perfusion and oxygenation. 
Biochemical and histological analysis 
Serum troponin T (TnT) and serum creatinine kinase activity (CK) were determined at baseline and at 
the end of the experiment using specific Troponin T Elisa Kit (KA3319, Abnova, Tapei City, Taiwan) and 
creatinine kinase assay kit (ab155901, Abcam, Cambridge, MA). 
At the end of the experiment animals were sacrificed through an overdose of anaesthesia (6% of 
sevoflurane, 1.5 mg/kg of vecuronium and 300 mg/kg of potassium chloride). Postmortem samples of left 
ventricle and left atrium were removed and fixed in 4% formaldehyde for histological analysis. Different 
areas of the heart were embedded in paraffin wax to prepare sections for light microscopy and stained for 
routine histological examination (hematoxylin-eosin). The histological examinations were carried out by a 
pathologist who was blinded to group assignments of these piglets.  
Statistical analysis 
Data was analysed using JMP statistical discovery software (version 8, SAS Institute Inc., North 
Carolina). One-way ANOVA was performed to assess time point differences in gas exchange, 
cardiovascular parameters and systemic oxygenation and perfusion as a function of group. Comparisons 
of results at all-time points were performed by two-way repeated-measures ANOVA as a function of group 
and time. Comparison of measured values before and after dobutamine administration was assessed by 
Student’s paired t test. Simple linear correlation analysis was used to assess the relationship between 
SVCF measurements and CI measurements. A p< 0.05 was considered statistically significant. Values 
are expressed as mean ± SD. 
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Table 1. Gas exchange, acid-base balance and lactate concentration in newborn piglets during hypoxia 
and dobutamine infusion 
 Baseline Hypoxia DI 1st dose DI 2nd dose Final 
Control 7.32±0.02 6.81±0.08 § 6.98±0.12 7.11±0.17 7.15±0.13 
L-M 7.31±0.05 6.96±0.09 § 7.15±0.10* 7.27±0.03* 7.27±0.02 pH 
M-H 7.36±0.05 6.91±0.08 § 7.16±0.10* 7.25±0.04* 7.26±0.07 
Control 45±6 44±7 39±4 40±4 42±5 
L-M 48±10 41±4 47±10 39±5 45±4 
PaCO2 
(mmHg) 
M-H 43±2 44±7 46±5* 47±6* 47±7 
Control 9.6±1.8 2.5±1.6 § 8.8±2.3 8.9±1.7 9.0±1.8 
L-M 9.8±0.9 2.3±0.8 § 8.7±1.6 8.0±1.5 8.4±1.0 CaO2 (ml/dl) 
M-H 9.3±2.0 1.7±0.1 § 8.3±2.2 8.0±1.3 8.0±1.4 
Control -3.3±2.9 -24.6±2.3 § -20.3±4.2 -14.9±6.8 -14.8±8.6 
L-M -2.3±2.8 -22.2±3.4 § -12.1±2.4* -8.4±1.2 -5.5±1.1* BE (mmol/l) 
M-H -1.7±2.6 -24.9±1.2 § -11.2±3.6* -6.3±2.3* -5.5±3.8* 
Control 1.5±0.7 16.7±3.6 § 13.3±4.0 9.6±5.4 7.8±6.0 
L-M 1.3±0.3 18.1±1.3 § 6.4±1.7* 2.9±1.4* 2.8±1.2 Lactate (mmol/l) 
M-H 1.4±0.2 16.5±0.1 § 6.2±1.9* 3.1±2.4* 2.9±3.0 
Control 38.7±0.7 38.0±0.7 38.1±0.5 38.3±0.5 38.5±0.8 
L-M 38.7±0.5 38.1±0.4 38.7±0.5 38.2±0.5 38.3±0.6 Temperature (ºC) 
M-H 38.3±0.4 38.4±0.2 38.3±0.6 38.3±0.3 38.1±0.4 
Control 49±3 43±13 41±5 41±5 42±6 
L-M 49±6 42±7 49±7 45±3 42±7 
End tidal 
CO2 
(mmHg) 
M-H 48±4 51±5 50±3 47±3 44±3 
(*) p<0.05 vs. control group (t test of paired means); (§) p<0.05 vs. baseline (t test of paired means). DI: 
dobutamine infusion; BE: base excess; CaO2: arterial oxygen content 
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FIGURE LEGENDS 
Figure 1. Correlation between superior vena cava flow (SVCF) and cardiac index (CI). The regression line 
and correlation coefficient (r2 = 0.645) demonstrate a significant linear relationship (p<0.0001) 
Figure 2. (A) Mean arterial blood pressure (MABP) and (B) heart rate (HR) in control group (white circle), 
low to medium dobutamine (L-M) dose group (black triangle) and medium to high dobutamine (M-H) dose 
group (black square). Data are expressed as mean and SD. *P<0.05 vs. Control group (one-way 
ANOVA), §P<0.05 vs. pretreatment (Student’s paired t test) and †P<0.05 vs. Control group (two-way 
repeated-measures ANOVA as a function of group and time) 
Figure 3. (A) Cardiac index (CI), (B) systemic vascular resistance index (SVRI) and (C) stroke volume 
index (SVI) in control group (white circle), low to medium dobutamine (L-M) dose group (black triangle) 
and medium to high dobutamine (M-H) dose group (black square). Data expressed as mean and SD. 
*P<0.05 vs. Control group (One-way ANOVA), §P<0.05 vs. pretreatment (Student’s paired t test) and 
†P<0.05 vs. Control group (two-way repeated-measures ANOVA as a function of group and time) 
Figure 4. (A) Oxygen delivery (OD), (B) oxygen consumption (VO2) and (C) oxygen extraction (FTOE) in 
control group (white circle), low to medium dobutamine (L-M) dose group (black triangle) and medium to 
high dobutamine (M-H) dose group (black square). Data expressed as mean and SD.  *P<0.05 vs. 
Control group (One-way ANOVA), §P<0.05 vs. pretreatment (Student’s paired t test) and †P<0.05 vs. 
Control group (two-way repeated-measures ANOVA as a function of group and time) 
Figure 5. Experimental protocol. The arrows represents the points at which the data were recorded (DI: 
dobutamine infusion; FiO2: fraction of inspired oxygen; MABP: mean arterial blood pressure; HR: Heart 
rate; CVP: central venous pressure; CI: cardiac index; SVI: Stroke volume index; SVRI: Systemic 
vascular resistance index; CaO2: arterial oxygen content; OD: oxygen delivery; VO2: oxygen 
consumption; FTOE: systemic fractional oxygen extraction; pTOI: peripheral tissue oxygenation index; 
pIO2: peripheral intravascular oxygenation; TnT: troponin T; CK: creatine kinase).  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
 
 
